Top Markets
Coin of the day
RayzeBio, Inc. Common Stock RayzeBio, Inc. Common Stock

RayzeBio, Inc. Common Stock

RYZB
株式のランク #5675
RayzeBio, Inc. is dedicated to creating radiopharmaceutical therapies (RPTs)... RayzeBio, Inc. is dedicated to creating radiopharmaceutical therapies (RPTs) for oncology applications. Its primary therapeutic candidate, RYZ101, is currently advancing through Phase 3 clinical trials for the management of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The company's innovative pipeline also features RYZ801, a distinct peptide engineered to deliver Actinium-225 (Ac225) by targeting GPC3, intended for treating hepatocellular carcinoma (HCC). Additionally, RayzeBio is developing RYZ811, a companion diagnostic imaging agent comprising a peptide binder, a chelator, and Gallium-68 (Ga68). Another active development program involves a novel proprietary small molecule designed to target CA9, delivering Ac225 for potential use against clear cell renal cell carcinoma (ccRCC). The firm was established in 2020 and is headquartered in San Diego, California.
株価
$62.49
最終同期: 2024-03-06
時価総額
$2.52B
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 RayzeBio, Inc. Common Stock (RYZB)

カテゴリー

RayzeBio, Inc. Common Stock(RYZB)のEPS
2026 時点のEPS TTM: 0
RayzeBio, Inc. Common Stockの最新の財務報告と株価によると、同社の現在のEPS(TTM)は0です。2026年末には、EPSは0で、2026年のEPS0と同等でした。
RayzeBio, Inc. Common StockのEPS履歴(2026から2026まで)
各年末時点のEPS
EPS 変化
提供された日付のデータは十分ではありません。
同様の企業または競合他社のEPS
企業 EPS EPSの差
$17.32 -
US
$27.74 -
NL
$-7.98 -
US
$-5.29 -
AU
- -
CH